Profile data is unavailable for this security.
About the company
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.
- Revenue in USD (TTM)175.51m
- Net income in USD-78.02m
- Incorporated2009
- Employees300.00
- LocationAurinia Pharmaceuticals Inc#140, 14315 - 118 AVENUEVICTORIA T5L 4S6CanadaCAN
- Phone+1 (250) 744-2487
- Fax+1 (604) 369-4115
- Websitehttps://www.auriniapharma.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinovac Biotech Ltd | 420.88m | -359.71m | 639.90m | 3.56k | -- | -- | -- | 1.52 | -3.63 | -3.63 | 3.94 | 87.08 | 0.0292 | 2.75 | 0.6035 | 118,289.80 | -5.09 | 55.60 | -7.77 | 93.17 | -46.96 | 91.39 | -174.00 | 67.88 | 9.74 | -- | 0.0174 | -- | -92.30 | 53.64 | -98.73 | 33.12 | 102.27 | -- |
| Nuvation Bio Inc | 0.00 | -75.80m | 646.33m | 51.00 | -- | 0.9484 | -- | -- | -0.3463 | -0.3463 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -11.72 | -16.27 | -11.97 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -106.80m | 649.17m | 33.00 | -- | 5.47 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.82m | -21.43m | 649.65m | 100.00 | -- | 6.42 | -- | 7.66 | -0.4909 | -0.4909 | 1.94 | 2.31 | 0.6299 | 1.93 | 4.85 | 848,190.00 | -15.91 | -44.23 | -19.40 | -50.45 | 86.60 | -- | -25.26 | -181.13 | 5.27 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Disc Medicine Inc | 0.00 | -76.43m | 654.54m | 74.00 | -- | 1.87 | -- | -- | -3.49 | -3.49 | 0.00 | 14.17 | 0.00 | -- | -- | 0.00 | -26.90 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -60.37m | 687.26m | 96.00 | -- | -- | -- | -- | -1.39 | -1.39 | 0.00 | 1.14 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0368 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -54.42m | 693.54m | 50.00 | -- | 11.53 | -- | -- | -2.39 | -2.39 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -89.72 | -- | -105.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Evolus Inc | 202.09m | -61.69m | 703.35m | 273.00 | -- | -- | -- | 3.48 | -1.08 | -1.08 | 3.55 | -0.3578 | 1.10 | 4.12 | 7.63 | 740,238.10 | -33.62 | -40.92 | -45.33 | -59.74 | 69.54 | 65.43 | -30.52 | -80.46 | 2.10 | -3.47 | 1.21 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Aurinia Pharmaceuticals Inc | 175.51m | -78.02m | 704.29m | 300.00 | -- | 1.85 | -- | 4.01 | -0.5454 | -0.5454 | 1.23 | 2.63 | 0.3445 | 0.439 | 9.34 | 585,043.30 | -15.31 | -25.97 | -17.42 | -28.24 | 91.94 | -- | -44.45 | -137.64 | 4.99 | -- | 0.1925 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Arcturus Therapeutics Holdings Inc | 166.80m | -29.73m | 704.37m | 180.00 | -- | 2.52 | -- | 4.22 | -1.16 | -1.16 | 6.23 | 10.38 | 0.3792 | -- | 9.58 | 926,661.10 | -6.76 | -19.66 | -8.86 | -24.90 | -- | -- | -17.82 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Pliant Therapeutics Inc | 1.58m | -161.34m | 715.64m | 158.00 | -- | 1.50 | -- | 452.94 | -2.75 | -2.75 | 0.0269 | 7.90 | 0.0037 | -- | 1.59 | 10,000.00 | -37.40 | -33.24 | -39.82 | -35.39 | -- | -- | -10,211.14 | -360.29 | -- | -- | 0.0208 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| CARGO Therapeutics Inc | 0.00 | -98.15m | 719.56m | 116.00 | -- | 1.86 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 732.99m | 284.00 | -- | 3.60 | -- | 9.06 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Zentalis Pharmaceuticals Inc | 0.00 | -292.19m | 779.50m | 168.00 | -- | 1.78 | -- | -- | -4.56 | -4.56 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -50.65 | -47.40 | -57.28 | -54.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
Data as of Apr 25 2024. Currency figures normalised to Aurinia Pharmaceuticals Inc's reporting currency: US Dollar USD
21.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 9.54m | 6.59% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 8.92m | 6.17% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.70m | 1.87% |
| Goldman Sachs Asset Management LPas of 31 Dec 2023 | 1.93m | 1.33% |
| Geode Capital Management LLCas of 29 Feb 2024 | 1.57m | 1.09% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 1.49m | 1.03% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2023 | 1.42m | 0.98% |
| Teachers Advisors LLCas of 29 Feb 2024 | 1.30m | 0.90% |
| TIAA-CREF Investment Management LLCas of 29 Feb 2024 | 1.12m | 0.77% |
| SV Health Managers LLPas of 30 Sep 2023 | 1.04m | 0.72% |
More ▼
Data from 30 Sep 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
